肿瘤细胞治疗研究
英文原题：Emerging targets in gastroesophageal adenocarcinoma: what the future looks like.
胃食管腺癌（GEA）是一种异质性疾病，预后差。
胃食管腺癌（GEA）具有异质性，预后较差。化疗一直是转移性疾病治疗的基石。近期引入免疫治疗后，局限性和转移性疾病患者的生存结局均有所改善。除免疫治疗外，研究者还尝试通过了解GEA分子机制来改善患者生存，并据此发表了多种分子分型方案。本文综述GEA的新兴靶点，包括成纤维细胞生长因子受体和Claudin 18.2，以及针对这些靶点的药物；还讨论靶向已知靶点（如HER2和血管生成）的新型药物，以及CAR-T和SPEAR-T细胞等细胞疗法。
Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。
